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The prevalence of atopy is associated with a western lifestyle as illustrated by studies 49 
comparing neighboring regions with different socioeconomic backgrounds. Atopy might 50 
reflect various conditions differing in their susceptibility to environmental factors. 51 
OBJECTIVE 52 
To define phenotypes of atopic sensitization in early childhood and to examine their 53 
association with allergic diseases and hereditary background in Finland and Estonia 54 
METHODS 55 
The analysis included 1603 Finnish and 1657 Estonian children from the DIABIMMUNE 56 
multicenter young children cohort. Specific IgE levels were measured at age 3, 4 and 5 57 
respectively, and categorized into three CAP classes. Latent Class Analysis (LCA) was 58 
performed with the statistic software package poLCA in R.  59 
RESULTS 60 
Both populations differed in terms of socioeconomic status and environmental determinants 61 
such as pet ownership, farm-related exposure, time of playing outdoors and prevalence of 62 
allergic diseases (all p-values <0.001). Nevertheless, we found similar latent classes (LC) in 63 
both populations: an unsensitized class, a food class, two inhalant classes differentiating 64 
between seasonal and perennial aero-allergens, and a severe atopy class. The latter was 65 
characterized by high total and specific IgE levels and strongly associated with wheeze (odds 66 
ratio 5.64 [3.07-10.52] and 4.56 [2.35-8.52]), allergic rhinitis (22.4 [11.67-44.54] and 13.97 67 
[7.33-26.4]) and atopic eczema (9.39 [4.9-19.3] and 9.5 [5.2-17.5], for Finland and Estonia, 68 
respectively). Environmental differences were reflected in the larger seasonal inhalant atopy 69 
class in Finland though composition of classes was comparable between countries.   70 
CONCLUSION 71 
Despite profound differences in environmental exposures there may exist genuine patterns 72 
of atopic sensitization. The distribution of these patterns may determine the contribution of 73 















KEY MESSAGE 75 
• Previously identified latent classes of atopy were replicated in Finland and Estonia, two 76 
countries with different environmental exposures. 77 
• The inhalant atopy classes were related to atopic diseases with the strongest association for 78 
the highly sensitized severe atopy class. 79 
• The differential associations of LC with allergic disease and genetic T1D susceptibility might 80 
point towards distinct immunologic mechanisms linking the various forms of atopy to allergy 81 
and autoimmunity.  82 
CAPSULE SUMMARY 83 
In two countries differing fundamentally in environmental and socioeconomic determinants and 84 
sensitization rates, similar atopy classes were found regarding composition and disease relevance.  85 
KEY WORDS 86 
Latent Class Analysis, unsupervised clustering, IgE, atopy, allergy, diabetes type 1 risk, wheezing, 87 
Finland, Estonia, severe atopy 88 
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ABBREVIATIONS  92 
 93 
AIC Akaike Information Criterion 
BIC Bayesian Information Criterion 
CAP Carrier polymer system  
CL Confidence Limit  
DMT1 Diabetes mellitus type 1  
IgE Immunoglobulin E 
sIgE Specific Immunoglobulin E 
tIgE Total Immunoglobulin E 
ISAAC International Study of Asthma and Allergies in Childhood  
kU/L Kilo units per liter  
LC Latent Class  
LCA Latent Class Analysis  
MAS Multizentrische Allergiestudie  
OR  Odds Ratio  
PASTURE Protection Against Allergy: Study in Rural Environments 
SES Socioeconomic status  
TH1 T helper 1 cells  
TH2 T helper 2 cells 
















Allergic diseases are more prevalent in industrialized countries as compared to less affluent 96 
countries.1 These differences are most prominent in neighboring areas,2 which might be perceived as 97 
“living laboratories” in the analysis of atopic diseases.3 A prominent example presents Karelia, an 98 
area covering a Finnish and a Russian part, which differ strongly in atopy prevalence and standard of 99 
living. Another example for such an experiment “by nature” might be seen in the forty years of 100 
separation between East and West Germany, where the inner-German border constituted a gradient 101 
in standard of living. The prevalence of atopy was significantly lower in the Eastern part, but caught 102 
up with West Germany within a decade after reunification.4, 5 Besides atopy, also autoimmune 103 
disorders, such as type 1 diabetes mellitus (T1D), are on the rise in Western countries.6 For instance, 104 
a remarkably higher incidence of T1D was observed in Finnish school children under the age of 15 105 
years as compared to the incidence in Russian Karelia.7 In addition, a genetic predisposition has been 106 
proposed for T1D, which was encoded predominantly by HLA loci.8  107 
Atopy is known to be associated with allergic9-12 and autoimmune13-15 diseases. As these conditions 108 
emerge from different pathologies, the question arises whether they relate to different aspects of 109 
atopy and how these aspects can be disentangled. A variety of studies have sought to apply various 110 
classifications to atopy, e.g. by concentrations of allergen specific IgE, mono- versus polyvalent 111 
sensitization, or time course.9, 11, 16-21 In our hands, latent class analysis (LCA) proved to be a suitable 112 
instrument for integrating the three dimensions allergen specificity, levels of specific IgE (sIgE), and 113 
time course in a data-driven approach, thereby being largely immune from investigator bias.12 This 114 
methodology was used in PASTURE and MAS to cluster preschool children into 3 atopy phenotypes 115 
with respect to disease relevance. The severe atopy phenotype was strongly related to respiratory 116 
allergy and impaired lung function; the symptomatic phenotype included the inhalant classes and 117 
was associated with respiratory allergy to a lower extent and unrelated to lung function impairment. 118 
Finally, a benign atopy phenotype covered the food classes and was not associated to any allergic 119 
disease.12 We hypothesized that with this classification we might be able to understand, which atopy 120 
types were most susceptible to environmental influences or family background of allergy and 121 
autoimmunity. 122 
Therefore, the aim of this study was to replicate the previous LCA findings from two birth cohorts in 123 
the young children cohort of the DIABIMMUNE study (www.diabimmune.org) and to use the unique 124 
setting for a direct comparison of atopy phenotypes and their hereditary background between 125 
Finland and Estonia, two countries separated by the Baltic Sea and with different socioeconomic and 126 















METHODS  128 
STUDY DESIGN 129 
The DIABIMMUNE study was performed in urban or suburban areas of Tartu in Estonia and Espoo in 130 
Finland. Families with 3 year old children born between January 2006 and July 2008 were identified 131 
from population registers and invited for participation. Between September 2009 and July 2011, 132 
1574 children out of 5830 Finnish families and 1681 children out of 10152 Estonian families were 133 
enrolled in the young children cohort and followed-up for 2 years (www.diabimmune.org). Blood was 134 
taken at the age of 3 and 5 years; for children with high risk of diabetes and high IgE levels at 135 
recruitment (high risk subpopulation) an additional follow-up visit with blood sampling was 136 
performed at the age of 4 years. The DIABIMMUNE study was conducted in accordance with the 137 
Declaration of Helsinki and was approved by the local institutional review boards of the participating 138 
hospitals. 139 
QUESTIONNAIRES 140 
Information about atopic eczema, allergic rhinitis and wheezing was obtained by the validated 141 
questions from the International Study of Asthma and Allergies in Childhood (ISAAC).22 Furthermore, 142 
information about socioeconomic background, parental diseases, environmental factors, infections 143 
and medication was collected at age 3 and allergic disease status at age 5 by parental report. 144 
OUTCOME DEFINITIONS 145 
Concentrations of specific IgE antibodies (sIgE) to common food (hen´s egg, cow’s milk, peanut) and 146 
aero-allergens (cat, dog, house dust mite, timothy grass and birch pollen) was measured in a SFS-EN 147 
ISO/IEC 17025:2005- and SFS-EN ISO 15189:2007- accredited centralized laboratory at the Unit of 148 
Medical Research Unit, Seinäjoki Central Hospital, in Finland by using automated Phadia 250 149 
ImmunoCAP fluoroenzyme immunoassay analyzer (Phadia Diagnostics, Thermo Fisher Scientific). The 150 
analyses were carried out blind to the knowledge of the clinical and demographic data. 151 
Concentrations of at least 0.35 kU/L (corresponding to CAP class 1) were considered positive. We also 152 
assessed cut-off levels for CAP class 2 and 3 corresponding to 0.7 kU/L and 3.5 kU/L, respectively. 153 
Wheezing was defined as lifetime prevalence of wheeze up to the age of 5 years, while strong 154 
wheezing was characterized by four or more attacks within the year before the follow-up visit. 155 
Risk for T1D was assessed by HLA-DQ genotypes. Children with the DR3-DQ2 haplotype (the 156 
DQA1*05-DQB1*02 combination) and/or the DR4-DQ8 haplotype (DQB1*03:02/4 without the 157 















Selected were those tested positive for DQA1*05-DQB1*02 and/or DQB1*032/4, but without 159 
DRB1*0403/6 (DR4-DQ8), and negative for protective haplotypes.8 The risk was defined by the 160 
presence and combination of these HLA alleles.23 The three highest risk classes, conferring 161 
susceptibility to T1D, were grouped together against the no or very low risk class.  162 
STATISTICAL ANALYSIS 163 
The sIgE values were categorized into CAP classes at three cut-off levels (0.35 kU/L, 0.7 kU/L and 164 
3.5kU/L). For the LCA, the poLCA package in R 3.2. was used.24 We performed four longitudinal LCAs: 165 
two country specific models and two for each country within a high risk population a model with 166 
three time points of sIgE measurements (at ages 3, 4, and 5 years). Each individual was 167 
unambiguously assigned to the class for which the posterior probability was highest. Each latent class 168 
was deliberately labeled according to the most prevalent allergen specificities. Logistic regression 169 
models were calculated to assess the association of allergic diseases and risk for T1D with class 170 
membership. The unsensitized class served as reference group. Associations were reported as odds 171 
ratios (OR) with 95% confidence intervals (CI). Characteristics between countries were compared by 172 
Fisher´s exact test, Kruskal-Wallis test and logistic regression. P values less than 0.05 were considered 173 
statistically significant. Populations attributable risk fractions were based on the odds ratios for the 174 
respective disease and the prevalence of each LC. 175 
















The two study populations were equal in size (Table 1), but differed significantly with respect to 178 
socioeconomic status, environmental exposures, and parental diseases (Figure 1, Table E1). The risk 179 
of allergic diseases and sensitization to major allergens such as hen’s egg, cow’s milk, and birch were 180 
increased in Finland whereas only dust mite was substantially higher in Estonia (p-values <0.001, 181 
Figure 2).  182 
Children with available sIgE data at both time points did not differ from the entire population with 183 
respect to parental and children´s disease prevalence, exposure to farming, and socioeconomic 184 
patterns except for maternal education in Finland (Table E 2). The 4-class LCA models yielded 185 
consistently the lowest Bayesian information criterion (BIC) and the 6-class solution the lowest 186 
Akaike criterion (AIC), whereas entropy was maximized in the 4- and 5-class solutions (Table E 3). For 187 
interpretability and comparability with earlier studies, we performed main analyses with the 5-class 188 
solutions and sensitivity analyses with the other solutions.  189 
The LCs of the two countries were similar with respect to lead allergens (Figure 3 A/B): LC1 was an 190 
unsensitized class with an extremely low prevalence of sensitization. The food class LC2 was 191 
characterized by sensitization to egg and milk allergens with decreasing sIgE levels over time. The 192 
seasonal inhalant class LC3 was driven by sIgE to birch and the perennial inhalant class LC4 by cat sIgE 193 
combined with dog (Finland) or dust mite sIgE (Estonia). The smallest class, LC5, was characterized by 194 
sIgE to inhalant (both seasonal and perennial) allergens combined with food sIgE and was labelled 195 
severe atopy for the features listed below. 196 
Though the high-risk subpopulation was smaller in Estonia (17.0% versus 31.8% in Finland), LCA 197 
revealed similar classes and interpretations (Figure 3 C/D). The three measurement time points of 198 
the high-risk subpopulation demonstrated that the steepest increase in inhalant sIgE occurred before 199 
age 4 (Figure 3C/D).  200 
The distribution of LCs in the full sample reflected the higher sensitization rate in Finland with the 201 
most striking difference in LC3, the seasonal class (Figure 4). In contrast, the countries did not differ 202 
in overall sensitization in the high-risk subpopulations (Table E4). Across all class solutions in both 203 
countries, the severe atopy class LC5 harbored children with the highest concentrations of total IgE 204 
(tIgE) (Figure 5 and Figure E 1A). 205 
The upper panel of Figure 6 demonstrates a gradient in the associations of the individual LCs with 206 
wheeze, allergic rhinitis, and eczema in both countries. Besides a weak inverse association with 207 















corresponding to the benign atopy phenotype. However, the seasonal and the perennial classes were 209 
substantially related to all allergic diseases as a sign of symptomatic atopy. The strongest 210 
associations with disease were found for the severe atopy phenotype (LC 5). It was strongly 211 
associated with wheeze (OR=5.64 [3.07-10.52] and 4.56 [2.35-8.52]), allergic rhinitis (22.4 [11.67-212 
44.54] and 13.97 [7.33-26.4]) and atopic eczema (9.39 [4.9-19.3] and 9.5 [5.2-17.5], for Finland and 213 
Estonia, respectively). The lower panel of Figure 6 reveals an association of severe atopy (LC5) with 214 
family history of atopy, whereas in Estonia the T1D risk genotype predisposed to symptomatic atopy 215 
(LC3 and LC4) but not severe atopy (LC5). 216 
Despite its small size, the severe atopy class contributed prominently to wheeze, allergic rhinitis, and 217 
eczema as illustrated by population attributable risk fractions (PARFs, Figure 7). In Finland, however, 218 
the seasonal class (LC3) contributed most importantly to all disease. 219 
Similar disease associations were found for the 6-class solution of both countries (Figure E 1B) and 220 















DISCUSSION  222 
Regardless of substantial environmental and socioeconomic differences and different atopy rates 223 
between Finland and Estonia, the postulated latent classes of food, seasonal, perennial, and severe 224 
atopy were found in both countries with high consistency. These four latent classes corresponded to 225 
the previously established trichotomy of benign, symptomatic, and severe atopy as illustrated by 226 
various degrees of disease relevance, tIgE levels, and family history of atopy. The higher sensitization 227 
prevalence in Finland was mainly attributable to the seasonal inhalant class, which also explained the 228 
higher proportion of allergic disease in Finland as shown by the corresponding PARF. The severe 229 
atopy class was equal in size and explained equal shares of allergic rhinitis and wheeze in both 230 
countries. Seasonal atopy was associated with T1D risk in Estonia and by trend in Finland. 231 
Despite their geographical proximity and similar climate, the studied regions of Finland and Estonia 232 
differ in many environmental exposures. During the 20th century, the two countries experienced 233 
different social and economic developments.25 Combined with faster urbanization and a Western 234 
lifestyle the Finnish economy prospered rapidly after World War II. Estonia’s economic growth 235 
matured predominantly after the Fall of the Soviet Union.26 As proxy variables of socioeconomic 236 
disparity, we assessed data on annual household income and maternal education in the current 237 
analysis. Environmental exposures were represented by animal and pet exposure, environmental 238 
tobacco smoke, farm milk consumption and playing outdoors (Figure 1). This list is obviously 239 
incomplete; previous comparisons of East and West European countries suggest additional 240 
differences in indoor climate,27 pollution,28 pollen trends,29 and family size.30  241 
A striking finding of this analysis was the difference in disease prevalence between both countries, 242 
with wheeze and allergic rhinitis being more common in Finland. These dissimilarities haven been 243 
often observed between East and West Europe. For example, the incidence of allergic disease was 244 
found to be elevated in urban areas and in industrialized countries in comparison to the post socialist 245 
countries of Eastern Europe.31 An asthma diagnosis was more often observed in Swedish 246 
schoolchildren as compared to Estonian children.32 Similarly, the prevalence of atopic diseases was 247 
increased in West Germany in comparison to East Germany4 though levelling out within a decade 248 
after reunification.5  249 
In Karelia, another interface between East and West, a gradient in asthma prevalence and atopic 250 
sensitization persists.33 While remaining stable in Russian Karelia, sensitization rates to pollen and to 251 
cat increased from 1997 to 2007 in the Finnish part of Karelia. Similarly, sensitization rates differed 252 
between Swedish and Polish schoolchildren.34 Even within Poland, differences were noted: In urban 253 















A similar gradient was observed between the city of Montreal and Prince Edward Island as a rural 255 
region of Canada.36 256 
The overall gradient in sensitization between Finland and Estonia observed in this study fits well into 257 
this picture. However, the forms of atopic sensitization follow the same pattern irrespectively of the 258 
environmental discrepancies. Only in the class of perennial sensitization the lead allergen differed. 259 
Whereas in Finnish children the perennial class was dominated by sIgE to cat, in Estonia sIgE to mite 260 
was most prevalent in this class. House dust mite sIgE might be more a marker for exposure,37 which 261 
might be limited in Finland due to its higher latitude. At least for Swedish regions a lack of dust mites 262 
has been described.38 263 
The described gradient in atopic sensitization can, however, resolve in response to environmental 264 
changes within a few years as illustrated by the rapid assimilation of atopy prevalence within 265 
Germany5 or between rural and urban Poland.39 Thus, atopy may virtually mirror environmental 266 
influences and illustrate the plasticity of the immune system also in adulthood.40 The question now 267 
arises what atopy actually means. 268 
We have previously classified atopy forms by latent class analysis in two birth cohorts, i.e. the 269 
Multicenter Allergy Study (MAS), conducted in five major cities in Germany, and the Protection 270 
Against Allergy: Study in Rural Environments (PASTURE), comprising children living in rural areas of 271 
five European countries.12 Like in MAS and PASTURE, levels of sIgE in this study were found to be 272 
generally increasing from 3 to 5 years of age except for food sIgE.  273 
The gradient of disease relevance previously detected in MAS and PASTURE was replicated in the two 274 
arms of the DIABIMMUNE study under investigation: Benign atopy included classes with sIgE only to 275 
food and without any disease association, though MAS revealed one food class and PASTURE two 276 
food classes. Symptomatic atopy reflected the inhalant classes (a seasonal and a perennial class in 277 
MAS and a single inhalant class in PASTURE) with their moderate associations with chronic 278 
inflammatory conditions such as allergic rhinitis, atopic eczema, and wheezing. Consistently with 279 
findings from MAS and PASTURE, severe atopy was characterized by the highest risk for all the above 280 
diseases and high sIgE levels to various allergens (“polysensitization”). In MAS and PASTURE, the 281 
severe atopy classes were strongly correlated with impaired lung function thereby contrasting with 282 
the other inhalant classes,41 which is of specific clinical interest. Despite a slightly different approach, 283 
also the Manchester and Isle of Wight studies revealed a similar association of a highly sensitized 284 
class with reduced lung functioning at the age of 10 years.42 In the current analysis, pulmonary 285 















relation to total IgE supports the specific severity of this atopy from. Total IgE has well been 287 
described as a predictor for allergic diseases.10, 11, 43-45 288 
Furthermore, our findings are in line with a study observing a relation of asthma to an inhalant 289 
sensitization class with food co-sensitization.46 In another study highly sensitized children at the age 290 
of 2 were found to be five times more likely to develop asthma within the following 2 years.20 291 
Likewise, the additional follow up at age 4 of the present study allowed an analysis of the dynamics 292 
of sIgE between ages 3 and 5, a time window not well covered by previous analyses.12 Here we found 293 
sIgE levels to increase particularly before age 4 years, suggesting this period to be critical for the 294 
development of (severe) atopic sensitization. This may have clinical implications, because atopy-295 
related asthma forms (“late onset wheeze”) often manifest after age 4.47 This asthma form is 296 
characterized by a loss of lung function,47 which might be prevented if these children were identified 297 
early in life.21  At least there is evidence for improvement of asthma by reducing IgE level by 298 
monoclonal antibodies.48 299 
The rise of both atopic and autoimmune diseases challenged the TH1/TH2 paradigm, which originally 300 
suggested an antagonism of TH1 and TH2 dominated immune conditions and diseases.
6 However, the 301 
concomitant occurrence of TH1 and TH2 prone diseases like atopy and diabetes suggests common 302 
genetic traits.49 Interestingly we found the hereditary predisposition to T1D to be associated with the 303 
inhalant LCs but not with severe atopy. This finding was robust over the four- to six-class solutions of 304 
LCA in Estonia and seen by trend in Finland. In contrast to the hereditary background of T1D, family 305 
history of atopy was most strongly associated with LC severe atopy. This class also exhibited the 306 
strongest associations with atopic diseases in the children as illustrated by allergic rhinitis and 307 
asthma, which in the present analysis was represented by wheeze at age 5 years. The rather low 308 
prevalence of autoimmune diseases in this young study population precluded a further investigation 309 
into the associations of atopy and autoimmune diseases.50, 51 Nevertheless the described findings 310 
support the concept that atopy consists of various different entities, some being associated with 311 
autoimmunity and susceptibility to environmental exposures, whereas others reflecting more 312 
genetically determined forms predisposing to TH2 diseases. 313 
The DIABIMMUNE study was mainly set up to study the development of T1D and the immunologic 314 
pathways involved thereby explaining the relatively sparse data on asthma and atopic diseases. In 315 
particular, the definition of eczema was not sufficiently precise thereby leaving room for 316 
interpretation between country-specific medical cultures. This may explain the different PARFs of 317 















On the other hand, the DIABIMMUNE study provided the unique opportunity to address the 319 
relationship between atopy and T1D. In fact, the hygiene hypothesis of asthma and allergies has 320 
stimulated a vivid debate whether infections in early childhood could foster or protect from ß-cell 321 
autoimmunity.52-54 An argument for the protective role of infections was the inverse relationship of 322 
T1D risk and sib ship size observed by Cardwell and colleagues and replicated in the present study 323 
(data not shown).55 Furthermore, changes in early microbial exposure altering the maturation of the 324 
immune system are currently a matter of debate. Vatanen et al. (2016) found that lipopolysaccharide 325 
from Bacteroides, which impede immune signaling and reduce endotoxin tolerance, are more 326 
common in Finland than in Russian Karelia, providing a possible explanation for the persistent 327 
gradient in the burden of disease.56  328 
To evaluate the robustness of the associations found in this study, we performed sensitivity analyses 329 
with four- and six-class models. In the four-class model, the seasonal and perennial inhalant classes 330 
were grouped together, and this group associated significantly with the HLA-defined T1D risk alleles. 331 
Moreover, the severe atopy class maintained the highest odds for the development of atopic 332 
diseases. The large sample size also allowed for a robust model with six classes, which separated LC 333 
severe atopy into a class with higher and a smaller class with relatively lower sIgE levels to seasonal 334 
allergens and moderate disease relevance. The latter dichotomy may again refine the 335 
characterization of severe atopy. Solutions with 7 or more classes were not explored due to the 336 
sample size, which may lead to insufficiently small class sizes.42 337 
CONCLUSION 338 
Taken together, we found very similar patterns of latent classes in both countries despite substantial 339 
differences in socioeconomic and environmental factors and distribution of single allergen 340 
specificities. The seasonal inhalant class seems to be most susceptible to environmental influences as 341 
reflected by substantially differing PARFs between two different countries. The phenomenon of 342 
severe atopy was mainly determined by elevated levels of sIgE and tIgE. The differential associations 343 
of LCs with allergic diseases and genetic T1D susceptibility might point towards distinct immunologic 344 
mechanisms linking the various forms of atopy to allergy and autoimmunity, which may be driven by 345 
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TABLE 1: STUDY POPULATION WITH COMPLETE DATA FOR QUESTIONNAIRES AND IGE 354 
MEASUREMENT AT RECRUITMENT AND FOLLOW-UP 355 
 
Finnish study population Estonian study population 
 
N % N % 
Age 3     
Recruitment 1603 100 1657 100 
Main questionnaire 1517 94.6 1236 74.6 
Environmental exposure 1525 95.1 1636 98.7 
IgE Measurement 1506 93.9 1635 98.7 
Age 5     
Main questionnaire 1338 83.3 828 50.0 
Allergy questionnaire 1328 82.8 1320 79.7 
Autoimmune disease form 1273 79.4 607 36.6 
IgE Measurement 1349 84.1 1291 78.0 
Age 3 and 5     
Complete IgE data 1124 70.1 1165 70.3 
 356 















LEGEND TO FIGURES  358 
FIGURE 1: DIFFERENCES IN POPULATION CHARACTERISTICS BETWEEN FINLAND AND ESTONIA 359 
All p-values < 0.001. 360 
FIGURE 2: PREVALENCE OF ALLERGIC DISEASES AND ATOPIC SENSITIZATION (SIGE ≥ 0.35 KU/L) IN 361 
FINLAND AND ESTONIA 362 
* ISAAC questions 363 
FIGURE 3: PREVALENCE OF POSITIVE IGE FOR THE 5-CLASS SOLUTIONS 364 
Perennial inhalant allergen specificities: dark blue = cat, light blue = dog, very light blue = dust mite 365 
Seasonal inhalant allergen specificities: light green = birch, dark green = timothy 366 
Food allergen specificities: red = peanut, orange = milk, yellow = egg 367 
The full samples included 1124 children in Finland and 1165 children in Estonia, whereas the high-risk 368 
population comprised 357 and 198 children, respectively. 369 
FIGURE 4: DISTRIBUTION OF THE LATENT CLASSES BY COUNTRY 370 
The distribution of class sizes differs significantly between countries (p<0.001). 371 
FIGURE 5: LEVELS OF TOTAL IGE ACROSS LCA AT 5 YEARS 372 
Levels of total IgE increase significantly over the latent classes (p<0.001 for all panels). 373 
FIGURE 6: ASSOCIATIONS OF LATENT CLASSES WITH DISEASES AND HEREDITARY BACKGROUND 374 
FI = Finland, EE = Estonia. Odds ratios are given with 95%-confidence intervals. There were many 375 
missing values for maternal and paternal history of atopy in the Estonian population as indicated by 376 
smaller symbols for the effect estimate. T1D = Type 1 diabetes mellitus risk represented by HLA-DQ 377 
risk alleles 378 
FIGURE 7: POPULATION ATTRIBUTABLE RISK FRACTIONS BY LATENT CLASSES 379 
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FIGURE E 1: THE 6-CLASS SOLUTION 31 
A: Levels of total IgE across latent classes 32 
B: Associations of latent classes with diseases and hereditary background  33 
 34 
FIGURE E 2: DISEASE ASSOCIATIONS IN THE HIGH-RISK POPULATION 35 
Due to a lower sample size and empty cells associations could not be calculated for eczema. 36 
T1D = Type 1 diabetes mellitus risk represented by HLA-DQ risk alleles 37 
















TABLE E 1: DESCRIPTION OF STUDY POPULATION BY CENTERS 40 
 Finnish study population Estonian study population  
 Total 
no.  




Male  792 49.4 76 858 51.8 12 0.660 





Low 243 15.2 192 511 30.8 104 <0.001 
Middle 581 36.2 934 56.4 




Low 270 16.8 273 377 22.8 123 <0.001 
High  1149 71.7  1246 75.2  
Smoking Inside 3 years 277 18.3  480 39.0  <0.001 
Environmental ambience  
Play outdoors  Daily 1378 81.3 84 1132 64.8 21 <0.001 
Weekly 115 6.8 300 17.2 
seldom 26 1.5 204 11.7 
Farming 17 1.1 57 90 7.3 43 <0.001 
Visit of barn Daily 5 0.3 45 39 3.2 71 <0.001 
Occasionally 119 7.9 44 259 21.0 62 <0.001 
Farm Milk 
Consumption 
Daily/Weekly 2 0.1 173 254 15.3 113 <0.001 
Occasionally  5 0.3  115 6.9   
Never 1514 94.5  1266 76.4   
Cat at home 133 8.3 92 241 14.5 427 <0.001 
Parental Diseases 
Parental Diabetes 161 10.0 76 56 3.4 12 <0.001 
Paternal Asthma 99 6.2 76 37 2.3 12 <0.001 
Maternal Asthma  120 7.5 76 48 2.9 12 <0.001 
For the comparison of study centers by characteristics in Table E1, p-values were derived by Fisher´s 41 


















TABLE E 2: CHILDREN WITH AVAILABLE IGE VALUES AT BOTH TIME POINTS 46 







 included excluded p-value included excluded p-value 
Gender Male 566 102 0.227 284 30 0.199 




Low 693 86 0.501 241 33 0.278 
High  521 114 291 33 
Maternal 
education 
Low 166 23 0.027 150 23 0.411 
Intermediate 411 74 309 38 
High  469 111 80 6 
Farming* 14 3 0.583 62 28 0.631 
Allergic Rhinitis* 184 24 0.051 104 15 0.884 
Atopic eczema at age 3* 332 61 0.626 136 23 0.363 
Wheezing* 257 59 0.189 133 18 0.999 
Parental Asthma* 139 26 0.911 27 2 0.761 
Paternal Diabetes* 120 15 0.085 13 2 0.680 
 47 
*Binary variables, only positive (=yes) data shown  48 
P-values were derived by Fisher´s Exact Test or Kruskall-Wallis Test.  49 
 50 















TABLE E 3: MODEL FIT CRITERIA 52 
  Finland Estonia 




4 11153 12113 95.99 % 9476 10463 95.93 % 
5 11010 12211 96.45 % 9385 10619 96.28 % 




4 7476 8573 99.45 % 4381 5338 99.37 % 
5 7383 8756 99.49 % 4368 5565 99.49 % 
6 7344 8992 99.31 % 4410 5847 99.53 % 
 53 
 54 
TABLE E 4: DISTRIBUTION OF CLASSES IN THE HIGH-RISK POPULATION 55 
Center LC1 LC2 LC3 LC4 LC5 
Finland 57% 15% 15% 9% 4% 
Estonia 58% 20% 8% 9% 7% 
The distribution of classes of the high risk subpopulation varies in size between the countries with 56 
borderline significance (p=0.070).”    57 
TABLE E5: ODDS RATIOS TO FIGURE 6 IN THE MAIN BODY  58 
Country Latent class Condition Odds ratio [95%-CI] p-value 
EE LC 2 Wheeze ever 0.74 [0.39-1.31] 0.33 
EE LC 3 Wheeze ever 1.95 [0.94-3.74] 0.056 
EE LC 4 Wheeze ever 2.48 [1.08-5.16] 0.021 
EE LC 5 Wheeze ever 4.48 [2.29-8.58] < 0.001 
EE LC 2 Allergic rhinitis 0.81 [0.4-1.51] 0.537 
EE LC 3 Allergic rhinitis 3.22 [1.62-6.05] < 0.001 
EE LC 4 Allergic rhinitis 3.86 [1.73-7.92] < 0.001 
EE LC 5 Allergic rhinitis 11.02 [5.75-21.12] < 0.001 
EE LC 2 Eczema 0.86 [0.47-1.48] 0.608 
EE LC 3 Eczema 2.1 [1.03-3.94] 0.03 
EE LC 4 Eczema 2.05 [0.86-4.39] 0.078 
EE LC 5 Eczema 9.21 [4.85-17.29] < 0.001 
EE LC 2 Maternal atopy 1.16 [0.51-2.36] 0.704 
EE LC 3 Maternal atopy 1.13 [0.32-3.03] 0.834 
EE LC 4 Maternal atopy 0.55 [0.03-2.89] 0.572 
EE LC 5 Maternal atopy 2.94 [0.63-10.91] 0.124 
EE LC 2 Paternal atopy 1.16 [0.49-2.46] 0.714 
EE LC 3 Paternal atopy 1.73 [0.57-4.39] 0.286 
EE LC 4 Paternal atopy 2.36 [0.52-8] 0.2 
EE LC 5 Paternal atopy 3.42 [0.72-12.68] 0.082 
EE LC 2 T1D risk genotype 0.7 [0.4-1.17] 0.199 
EE LC 3 T1D risk genotype 1.8 [0.93-3.29] 0.064 















EE LC 5 T1D risk genotype 0.69 [0.24-1.63] 0.447 
FI LC 2 Wheeze ever 0.85 [0.57-1.26] 0.442 
FI LC 3 Wheeze ever 2.46 [1.62-3.71] < 0.001 
FI LC 4 Wheeze ever 2.27 [1.21-4.18] 0.009 
FI LC 5 Wheeze ever 5.1 [2.66-9.97] < 0.001 
FI LC 2 Allergic rhinitis 0.51 [0.29-0.84] 0.011 
FI LC 3 Allergic rhinitis 9.87 [6.42-15.18] < 0.001 
FI LC 4 Allergic rhinitis 4.62 [2.48-8.41] < 0.001 
FI LC 5 Allergic rhinitis 16.95 [8.33-37.34] < 0.001 
FI LC 2 Eczema 1.01 [0.7-1.45] 0.94 
FI LC 3 Eczema 2.83 [1.9-4.26] < 0.001 
FI LC 4 Eczema 2.29 [1.25-4.18] 0.007 
FI LC 5 Eczema 11.59 [5.31-28.79] < 0.001 
FI LC 2 Maternal atopy 0.82 [0.57-1.16] 0.274 
FI LC 3 Maternal atopy 1.48 [0.97-2.23] 0.066 
FI LC 4 Maternal atopy 1.11 [0.58-2.05] 0.744 
FI LC 5 Maternal atopy 2.34 [1.23-4.53] 0.01 
FI LC 2 Paternal atopy 0.99 [0.68-1.4] 0.936 
FI LC 3 Paternal atopy 1.21 [0.78-1.84] 0.393 
FI LC 4 Paternal atopy 0.88 [0.44-1.67] 0.704 
FI LC 5 Paternal atopy 2.29 [1.21-4.39] 0.011 
FI LC 2 T1D risk genotype 0.79 [0.52-1.19] 0.276 
FI LC 3 T1D risk genotype 1.28 [0.8-1.99] 0.283 
FI LC 4 T1D risk genotype 0.95 [0.44-1.88] 0.899 
FI LC 5 T1D risk genotype 1 [0.44-2.05] 0.999 
 59 
TABLE E6: ISAAC QUESTIONS  60 
Variable ISAAC Question Response options Operationalized 
Atopic Eczema Has your child ever 
had an itchy rash 
which was coming 





Wheeze ever Has your child ever 
had wheezing or 
whistling in the chest 





Strong Wheeze  How many attacks of 
wheezing has your 
child had in the past 
12 months 
None 
1 to 3 
4 to 12 
More than 12  
More than 4 attacks 
in the last 12 months  
Allergic Rhinitis In the past 12 
months, has your 
child had a problem 
with sneezing or a 


















nose when he/she 
DID NOT have a cold 
or the flu?  
 61 
